SGLT2i for heart transplant recipients
Treatments studied
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You received a heart transplant at least 3 months ago.
- Your kidney function (eGFR) is 20 or higher.
- You do not have type 1 diabetes.
- Your blood sugar control (HbA1C) is 10% or lower.
- You have not taken SGLT2i medication in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help protect the kidneys and heart in people with chronic kidney disease or type 2 diabetes. If you have either condition, you might be able to join.
This trial tests a medicine called an SGLT2 inhibitor (which helps lower blood sugar) in people who have had a kidney transplant and do not have diabetes. The goal is to see if it can prevent new diabetes from developing after a transplant and help protect the transplanted kidney.
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests whether a diabetes medication called empagliflozin (an SGLT2 inhibitor) can help people who have had an islet transplant (TPIAT) better manage their blood sugar. It aims to see if it improves how well the transplanted islets work.
Hear when a new Heart Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.